MGX Logo

Metagenomi, Inc. Common Stock (MGX) Stock Forecast & Price Prediction

Live MGX Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$2.61

+0.16 (6.53%)

12 Month Price Forecast For MGX

$2.61
Current Price
$97.68M
Market Cap
6 Ratings
Buy 5
Hold 1
Sell 0
Wall St Analyst Ratings

Distance to MGX Price Forecasts

+857.9%
To High Target of $25.00
+551.3%
To Median Target of $17.00
+436.4%
To Low Target of $14.00

MGX Price Momentum

+5.2%
1 Week Change
-6.8%
1 Month Change
-78.5%
1 Year Change
-27.7%
Year-to-Date Change
-79.5%
From 52W High of $12.74
+62.1%
From 52W Low of $1.61

๐Ÿค” Considering Metagenomi (MGX)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 6:03 PM UTC

MGX Analyst Ratings & Price Targets

Based on our analysis of 7 Wall Street analysts, MGX has a bullish consensus with a median price target of $17.00 (ranging from $14.00 to $25.00). Currently trading at $2.61, the median forecast implies a 551.3% upside. This outlook is supported by 5 Buy, 1 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Yanan Zhu at Wells Fargo, projecting a 857.9% upside. Conversely, the most conservative target is provided by Mitchell Kapoor at HC Wainwright & Co., suggesting a 436.4% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

MGX Analyst Consensus

5
Buy
1
Hold
0
Sell

MGX Price Target Range

Low
$14.00
Average
$17.00
High
$25.00
Current: $2.61

Latest MGX Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for MGX.

Date Firm Analyst Rating Change Price Target
Dec 10, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Maintains $14.00
Nov 21, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Reiterates $7.00
Nov 20, 2024 Chardan Capital Geulah Livshits Buy Maintains $15.00
Oct 15, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Reiterates $7.00
Sep 6, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Reiterates $7.00
Sep 5, 2024 Chardan Capital Geulah Livshits Buy Maintains $15.00
Aug 21, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Maintains $7.00
Aug 19, 2024 Chardan Capital Geulah Livshits Buy Maintains $15.00
Aug 15, 2024 BMO Capital Kostas Biliouris Outperform Maintains $17.00
Jul 15, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Reiterates $10.00
May 15, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Reiterates $10.00
May 7, 2024 HC Wainwright & Co. Mitchell Kapoor Buy Initiates $10.00
May 2, 2024 JP Morgan Brian Cheng Neutral Downgrade $6.00
Mar 28, 2024 Chardan Capital Geulah Livshits Buy Maintains $21.00
Mar 5, 2024 TD Cowen Joseph Thome Outperform Initiates $0.00
Mar 5, 2024 Jefferies Maury Raycroft Buy Initiates $23.00
Mar 5, 2024 BMO Capital Kostas Biliouris Outperform Initiates $22.00
Mar 5, 2024 Wells Fargo Yanan Zhu Overweight Initiates $25.00
Mar 5, 2024 Chardan Capital Geulah Livshits Buy Initiates $21.00
Mar 5, 2024 JP Morgan Brian Cheng Overweight Initiates $16.00

Stocks Similar to Metagenomi, Inc. Common Stock

The following stocks are similar to Metagenomi based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Metagenomi, Inc. Common Stock (MGX) Financial Data

Metagenomi, Inc. Common Stock has a market capitalization of $97.68M with a P/E ratio of -1.4x. The company generates $55.08M in trailing twelve-month revenue with a -134.3% profit margin.

Revenue growth is -6.9% quarter-over-quarter, while maintaining an operating margin of -194.4% and return on equity of -30.3%.

Valuation Metrics

Market Cap $97.68M
Enterprise Value $-136,825,408
P/E Ratio -1.4x
PEG Ratio -0.9x
Price/Sales 1.8x

Growth & Margins

Revenue Growth (YoY) -6.9%
Gross Margin N/A
Operating Margin -194.4%
Net Margin -134.3%
EPS Growth N/A

Financial Health

Cash/Price Ratio +281.1%
Current Ratio 6.2x
Debt/Equity 18.0x
ROE -30.3%
ROA -14.8%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Metagenomi, Inc. Common Stock logo

Metagenomi, Inc. Common Stock (MGX) Company Overview

About Metagenomi, Inc. Common Stock

What They Do

Develops genetic therapeutics using genome editing.

Business Model

Metagenomi, Inc. operates by creating advanced genetic medicines utilizing its proprietary genome editing toolbox, which includes various innovative technologies. The company monetizes its research through development, option, and license agreements with partners such as Affini-T Therapeutics and Ionis Pharmaceuticals, allowing it to share costs and revenues from the commercialization of gene therapies.

Additional Information

Founded in 2016 and based in Emeryville, California, Metagenomi focuses on treating, preventing, or diagnosing human cancer, positioning itself in the rapidly growing genetic medicine sector.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

236

CEO

Dr. Brian Charles Thomas Ph.D.

Country

United States

IPO Year

2024

Metagenomi, Inc. Common Stock (MGX) Latest News & Analysis

MGX stock latest news image
Quick Summary

Metagenomi, Inc. (Nasdaq: MGX) CEO Brian C. Thomas will speak at TD Cowen's Health Care Conference on March 5, 2025, and the company will hold one-on-one investor meetings.

Why It Matters

Metagenomi's participation in a prominent healthcare conference highlights its strategic efforts to engage with investors and showcase its gene editing innovations, potentially influencing stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
MGX stock latest news image
Quick Summary

Metagenomi, Inc. has appointed Eric Bjerkholt, CFO of Mirum Pharmaceuticals, to its Board of Directors, effective January 27, 2025. He will serve on the Audit and Compensation committees.

Why It Matters

Eric Bjerkholt's appointment to Metagenomi's Board could enhance financial oversight and strategic direction, potentially leading to improved investor confidence and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
MGX stock latest news image
Quick Summary

Metagenomi, Inc. (MGX) is advancing MGX-001 for Hemophilia A towards regulatory interactions in 2025, with cash runway expected to support operations into 2027.

Why It Matters

Metagenomi's advancements in gene editing for Hemophilia A and cardiometabolic indications signal potential growth and innovation, enhancing investor confidence in future performance and product viability.

Source: GlobeNewsWire
Market Sentiment: Neutral
MGX stock latest news image
Quick Summary

Metagenomi, Inc. (Nasdaq: MGX) will present at the J.P. Morgan Healthcare Conference on January 15, 2025, at 4:30 p.m. PT, showcasing its gene editing technologies.

Why It Matters

Metagenomi's presentation at a major healthcare conference can attract investor interest, highlight advancements in gene editing, and potentially influence stock performance based on market reactions.

Source: GlobeNewsWire
Market Sentiment: Neutral
MGX stock latest news image
Quick Summary

Metagenomi, Inc. (Nasdaq: MGX) showcased its MGX-001 gene editing tool, highlighting its precision and safety in human cells, at the Nature Conference on December 11, 2024.

Why It Matters

Metagenomi's advancements in precise gene editing with no off-target effects could enhance its product pipeline, potentially leading to significant therapeutic breakthroughs and increased investor confidence.

Source: GlobeNewsWire
Market Sentiment: Neutral
MGX stock latest news image
Quick Summary

A nonhuman primate study shows sustained therapeutic levels of Factor VIII activity for over 16 months, indicating potential for long-term efficacy in treatments.

Why It Matters

Sustained Factor VIII activity in NHP studies signals potential for effective hemophilia treatments, which could boost company valuations and attract investment in biopharma sectors.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About MGX Stock

What is Metagenomi, Inc. Common Stock's (MGX) stock forecast for 2025?

Based on our analysis of 7 Wall Street analysts, Metagenomi, Inc. Common Stock (MGX) has a median price target of $17.00. The highest price target is $25.00 and the lowest is $14.00.

Is MGX stock a good investment in 2025?

According to current analyst ratings, MGX has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.61. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for MGX stock?

Wall Street analysts predict MGX stock could reach $17.00 in the next 12 months. This represents a 551.3% increase from the current price of $2.61. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Metagenomi, Inc. Common Stock's business model?

Metagenomi, Inc. operates by creating advanced genetic medicines utilizing its proprietary genome editing toolbox, which includes various innovative technologies. The company monetizes its research through development, option, and license agreements with partners such as Affini-T Therapeutics and Ionis Pharmaceuticals, allowing it to share costs and revenues from the commercialization of gene therapies.

What is the highest forecasted price for MGX Metagenomi, Inc. Common Stock?

The highest price target for MGX is $25.00 from Yanan Zhu at Wells Fargo, which represents a 857.9% increase from the current price of $2.61.

What is the lowest forecasted price for MGX Metagenomi, Inc. Common Stock?

The lowest price target for MGX is $14.00 from Mitchell Kapoor at HC Wainwright & Co., which represents a 436.4% increase from the current price of $2.61.

What is the overall MGX consensus from analysts for Metagenomi, Inc. Common Stock?

The overall analyst consensus for MGX is bullish. Out of 7 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $17.00.

How accurate are MGX stock price projections?

Stock price projections, including those for Metagenomi, Inc. Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.